<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139540</url>
  </required_header>
  <id_info>
    <org_study_id>201204023</org_study_id>
    <nct_id>NCT02139540</nct_id>
  </id_info>
  <brief_title>Nitrous Oxide as Treatment for Major Depression - a Pilot Study</brief_title>
  <official_title>Nitrous Oxide as Treatment for Major Depression - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder (MDD) is a global medical problem with significant shortcomings in
      current therapy. Chief among these is the delay between initiation of pharmacologic therapy
      and clinical improvement in symptoms. Recently ketamine, an NDMA-receptor antagonist has been
      shown to rapidly and effectively reverse the symptoms of MDD. Nitrous oxide, another
      NMDA-receptor antagonist, may produce the same effect with a cleaner side-effect profile and
      perhaps without the need for intravenous access and anesthesia personnel. Therefore, we
      propose conducting a pilot randomized placebo controlled double-blind crossover study in
      which patients will receive up to 50% nitrous oxide in oxygen or up to 50% oxygen in air for
      a period of one hour in addition to standard medical therapy. Depression severity will be
      assessed by a blinded observer pre-treatment, 30 minutes and 2 hours post treatment using the
      Hamilton depression rating scale.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will study 20 patients with non-treatment resistant major depression and 20 patients with
      treatment-resistant major depression, defined as failure of at least 2 antidepressants in the
      current depressive episode and 3 lifetime medication failures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale HDRS-21</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>(21-point Hamilton Depression Rating Scale) Scoring is based on the first 17 items on the 21 point scale. Eight items are scored on a 5-point scale, ranging form 0=not present to 4= severe. Nine are scored from 0-2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quick Inventory of Depressive Symptomatology - Self Report - QIDS -SR</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>[Quick Inventory of Depressive Symptomatology - Self Report] An item-by-item severity scale of 0 to 3, with possible total scores ranging from 0 to 84. The items on the scale are added together for a total score. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>N2O/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First session: Nitrous oxide Second session: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/N2O</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First session: Placebo Second session: Nitrous Oxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide</intervention_name>
    <description>Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or &quot;placebo&quot; (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.</description>
    <arm_group_label>N2O/Placebo</arm_group_label>
    <arm_group_label>Placebo/N2O</arm_group_label>
    <other_name>Laughing Gas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
    <arm_group_label>N2O/Placebo</arm_group_label>
    <arm_group_label>Placebo/N2O</arm_group_label>
    <other_name>50% nitrogen [inert]/50% oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults 18-65 years of age

          2. Major depressive disorder without psychosis with as determined by structured interview
             using the Mini-International Neuropsychiatric Interview (MINI).

             (baseline )

          3. HDRS-21 score of &gt;18

          4. Good command of the English language

        Exclusion Criteria:

        History of:

          1. Bipolar disorder

          2. Schizoprenia

          3. Schizoaffective disorder

          4. Obsessive-compulsive disorder, panic disorder

          5. Substance abuse or dependence (except for remote substance abuse or dependence with
             remission at least 1 year prior to the study and except for nicotine use disorders)

          6. Axis II diagnoses that may interfere with the patient's ability to improve on nitrous
             oxide

          7. Acute medical illness that may pose subject at risk during nitrous oxide
             administration

          8. Active suicidal intention (inability to contract for safety)

          9. Active psychotic symptoms

         10. Patients with significant pulmonary disease and/or requiring supplemental oxygen

         11. Contraindication against the use of nitrous oxide:

               1. Pneumothorax

               2. Bowel obstruction

               3. Middle ear occlusion

               4. Elevated intracranial pressure

               5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12

               6. Pregnant patients

               7. Breastfeeding women

         12. Previous administration of NMDA-receptor antagonists (e.g., ketamine) within the last
             3 months

         13. Current electro-convulsive therapy treatment

         14. Any active suicidal ideation, intention, or planning (clinical assessment of
             suicidality will be used)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Nagele, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>January 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21 Participants were consented, however only 20 continued.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>N2O/Placebo</title>
          <description>First session: Nitrous oxide Second session: placebo
Nitrous Oxide: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or &quot;placebo&quot; (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.
Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
        </group>
        <group group_id="P2">
          <title>Placebo/N2O</title>
          <description>First session: Placebo Second session: Nitrous Oxide
Nitrous Oxide: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or &quot;placebo&quot; (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.
Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N2O/Placebo</title>
          <description>First session: Nitrous oxide Second session: placebo
Nitrous Oxide: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or &quot;placebo&quot; (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.
Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
        </group>
        <group group_id="B2">
          <title>Placebo/N2O</title>
          <description>First session: Placebo Second session: Nitrous Oxide
Nitrous Oxide: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or &quot;placebo&quot; (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.
Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="30" upper_limit="55"/>
                    <measurement group_id="B2" value="48" lower_limit="30" upper_limit="55"/>
                    <measurement group_id="B3" value="48" lower_limit="30" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Depression Rating Scale HDRS-21</title>
        <description>(21-point Hamilton Depression Rating Scale) Scoring is based on the first 17 items on the 21 point scale. Eight items are scored on a 5-point scale, ranging form 0=not present to 4= severe. Nine are scored from 0-2.</description>
        <time_frame>baseline and 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Rating Scale HDRS-21</title>
          <description>(21-point Hamilton Depression Rating Scale) Scoring is based on the first 17 items on the 21 point scale. Eight items are scored on a 5-point scale, ranging form 0=not present to 4= severe. Nine are scored from 0-2.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.5" upper_limit="8.5"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.2" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary outcome (HDRS-21) was analyzed with a repeated-measures mixed effects linear model using restricted maximum likelihood estimation. To adjust for the observed carryover effect, the model included a randomization group term and a three-way interaction (treatment × time × randomization group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quick Inventory of Depressive Symptomatology - Self Report - QIDS -SR</title>
        <description>[Quick Inventory of Depressive Symptomatology - Self Report] An item-by-item severity scale of 0 to 3, with possible total scores ranging from 0 to 84. The items on the scale are added together for a total score. Higher scores mean worse outcome.</description>
        <time_frame>baseline and 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitrous Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quick Inventory of Depressive Symptomatology - Self Report - QIDS -SR</title>
          <description>[Quick Inventory of Depressive Symptomatology - Self Report] An item-by-item severity scale of 0 to 3, with possible total scores ranging from 0 to 84. The items on the scale are added together for a total score. Higher scores mean worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.3" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nitrous Oxide</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Washington University</organization>
      <phone>7737022544</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

